Lisa Shirreff

TL;DR: In this article, the authors demonstrate the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike protein receptor-binding domain displayed on an I53-50 protein nanoparticle scaffold (hereafter designated RBD-NP), to stimulate robust and durable neutralizing-antibody responses.

TL;DR: It is shown that a dual radionuclide–near-infrared probe allows for quantitative, longitudinal and non-invasive monitoring of the trafficking dynamics to draining lymph nodes of a model messenger RNA vaccine labelled with the probe.

TL;DR: In this paper, a clinical stage multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle (RBD-NP) vaccine was used to protect mice from SARS CoV 2 challenge after a single immunization.

TL;DR: High genomic diversity among the strains of M. marinum reveals high genomic diversity relative to other mycobacteria such as Mycobacterium tuberculosis, and it is suggested that these two clusters should be considered to represent two M.marinum subspecies.

TL;DR: Durable protection against Omicron BA.1 variant induced by a subunit SARS-CoV-2 vaccine comprising the receptor binding domain of the ancestral strain on the I53-50 nanoparticle adjuvanted with AS03 is demonstrated.